Ascletis Pharma, Inc. (1672) Stock Forecast & Price Target

Compare

8 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

1672 Analyst Ratings

Hold

0 Buy

1 Hold

0 Sell

Based on 1 analysts giving stock ratings to

Ascletis

Pharma, Inc.

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

1672 Stock 12 Month Forecast

Average Price Target

HK$12.84

▼(-24.07% Downside)

Based on 1 Wall Street analysts offering 12 month price targets for Ascletis Pharma, Inc. in the last 3 months. The average price target is HK$12.84 with a high forecast of HK$12.84 and a low forecast of HK$12.84. The average price target represents a -24.07% change from the last price of HK$16.91.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"3":"HK$3","7":"HK$7","11":"HK$11","15":"HK$15","-1":"-HK$1"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":12.84,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">HK$12.84</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":12.84,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">HK$12.84</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":12.84,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">HK$12.84</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,3,7,11,15],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Apr<br/>2024","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,14.54,14.409230769230769,14.278461538461539,14.147692307692306,14.016923076923076,13.886153846153846,13.755384615384616,13.624615384615383,13.493846153846153,13.363076923076923,13.232307692307693,13.10153846153846,12.97076923076923,{"y":12.84,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,14.54,14.409230769230769,14.278461538461539,14.147692307692306,14.016923076923076,13.886153846153846,13.755384615384616,13.624615384615383,13.493846153846153,13.363076923076923,13.232307692307693,13.10153846153846,12.97076923076923,{"y":12.84,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,14.54,14.409230769230769,14.278461538461539,14.147692307692306,14.016923076923076,13.886153846153846,13.755384615384616,13.624615384615383,13.493846153846153,13.363076923076923,13.232307692307693,13.10153846153846,12.97076923076923,{"y":12.84,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":0.86,"date":1690848000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.86,"date":1704067200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.86,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.86,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.01,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.63,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.98,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.06,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.5,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.02,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.97,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.65,"date":1761955200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":14.54,"date":1764547200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price TargetHK$12.84

Average Price TargetHK$12.84

Lowest Price TargetHK$12.84

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Ziyi Chen

Goldman Sachs

HK$14.75→HK$12.84

Hold

-24.07%

Downside

Reiterated

10/27/25

Goldman Sachs Reaffirms Their Hold Rating on Ascletis Pharma, Inc. (1672)

Wangbin Zhou

Citi

HK$20→HK$32

Buy

89.24%

Upside

Reiterated

08/25/25

Ascletis Pharma, Inc. (1672) Gets a Buy from CitiCiti analyst Wangbin Zhou raised the price target on Ascletis Pharma Inc (1672:HK) (OTC: ASCLF) to HK$32.00 (from HK$20.00) while maintaining a Buy rating.

Unknown Analyst

Guotai Haitong

Not Ranked

Guotai Haitong

HK$27.91

Buy

65.05%

Upside

Reiterated

08/17/25

Unknown Analyst

Soochow Securities

Not Ranked

Soochow Securities

HK$29.26

Buy

73.03%

Upside

Reiterated

08/16/25

Unknown Analyst

Soochow Securities

Not Ranked

Soochow Securities

HK$14.02

Buy

-17.09%

Downside

Reiterated

08/06/25

Unknown Analyst

China Securities International

Not Ranked

China Securities International

HK$19.93

Buy

17.86%

Upside

Reiterated

06/26/25

Unknown Analyst

Soochow Securities

Not Ranked

Soochow Securities

HK$11.88

Buy

-29.75%

Downside

Reiterated

06/05/25

Unknown Analyst

Guotai Haitong

Not Ranked

Guotai Haitong

HK$8.18

Buy

-51.63%

Downside

Reiterated

02/21/25

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Ziyi Chen

Goldman Sachs

HK$14.75→HK$12.84

Hold

-24.07%

Downside

Reiterated

10/27/25

Goldman Sachs Reaffirms Their Hold Rating on Ascletis Pharma, Inc. (1672)

Wangbin Zhou

Citi

HK$20→HK$32

Buy

89.24%

Upside

Reiterated

08/25/25

Unknown Analyst

Guotai Haitong

Not Ranked

Guotai Haitong

HK$27.91

Buy

65.05%

Upside

Reiterated

08/17/25

Unknown Analyst

Soochow Securities

Not Ranked

Soochow Securities

HK$29.26

Buy

73.03%

Upside

Reiterated

08/16/25

Unknown Analyst

Soochow Securities

Not Ranked

Soochow Securities

HK$14.02

Buy

-17.09%

Downside

Reiterated

08/06/25

Unknown Analyst

China Securities International

Not Ranked

China Securities International

HK$19.93

Buy

17.86%

Upside

Reiterated

06/26/25

Unknown Analyst

Soochow Securities

Not Ranked

Soochow Securities

HK$11.88

Buy

-29.75%

Downside

Reiterated

06/05/25

Unknown Analyst

Guotai Haitong

Not Ranked

Guotai Haitong

HK$8.18

Buy

-51.63%

Downside

Reiterated

02/21/25

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Ascletis Pharma, Inc.

1 Month

xxx

Success Rate

0/1 ratings generated profit

Average Return

-16.80%

reiterated a xxx

rating 4 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 0.00% of your transactions generating a profit, with an average return of -16.80% per trade.

3 Months

xxx

Success Rate

1/1 ratings generated profit

Average Return

+3.90%

reiterated a xxx

rating 4 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 100.00% of your transactions generating a profit, with an average return of +3.90% per trade.

1 Year

Wangbin ZhouCiti

Success Rate

1/1 ratings generated profit

Average Return

+3.50%

reiterated a buy rating 4 months ago

Copying Wangbin Zhou's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +3.50% per trade.

2 Years

xxx

Success Rate

1/1 ratings generated profit

Average Return

+3.50%

reiterated a xxx

rating 4 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +3.50% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

1672 Analyst Recommendation Trends

Rating

Aug 25

Sep 25

Oct 25

Nov 25

Dec 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, 1672 has received 0 Buy Ratings, 5 Hold Ratings, and 0 Sell Ratings. 1672 average Analyst price target in the past 3 months is 12.84.

Each month's total comprises the sum of three months' worth of ratings.

1672 Financial Forecast

1672 Earnings Forecast

Next quarter’s earnings estimate for 1672 is -HK$0.35 with a range of -HK$0.35 to -HK$0.35. The previous quarter’s EPS was -HK$0.10. 1672 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year 1672 has Performed in-line its overall industry.

1672 Sales Forecast

Next quarter’s sales forecast for 1672 is HK$0.00 with a range of HK$0.00 to HK$0.00. The previous quarter’s sales results were HK$1.16M. 1672 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year 1672 has Performed in-line its overall industry.

1672 Stock Forecast FAQ

What is HK:1672’s average 12-month price target, according to analysts?

Based on analyst ratings, Ascletis Pharma, Inc.’s 12-month average price target is 12.84.

What is HK:1672’s upside potential, based on the analysts’ average price target?

Currently there's no upside potential for HK:1672, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Ascletis Pharma, Inc. a Buy, Sell or Hold?

Ascletis Pharma, Inc. has a consensus rating of Hold, which is based on 0 buy ratings, 1 hold ratings and 0 sell ratings.

What is Ascletis Pharma, Inc.’s share price target?

The average share price target for Ascletis Pharma, Inc. is 12.84. This is based on 1 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is HK$12.84 ,and the lowest forecast is HK$12.84. The average share price target represents -24.07% Decrease from the current price of HK$16.91.

What do analysts say about Ascletis Pharma, Inc.?

Ascletis Pharma, Inc.’s analyst rating consensus is a Hold. This is based on the ratings of 1 Wall Streets Analysts.

How can I buy shares of Ascletis Pharma, Inc.?

To buy shares of HK:1672, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Ascletis Pharma, Inc. (1672) Stock Forecast & Price Target

1672 Analyst Ratings

1672 Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Ascletis Pharma, Inc.

1672 Analyst Recommendation Trends

1672 Financial Forecast

1672 Earnings Forecast

1672 Sales Forecast

1672 Stock Forecast FAQ

Detailed List of Analyst Forecasts